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The Global Uliliration of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries (GUSTO) trial is
large scale international trial of new myocardial reperfusion
strategies. The primary hypothesis is Ihat early and sostai nzd
coronary artery recanalization will be associated with a significant
reduction in mortality. The four regimens that are being tested are
1) streptokinase with subcutaneous heparin ; 2) streptokinase with
intravenous heparin; 3) accelerated recombinant tissue-type
plasminogen activator (rt-PA) with intravenous heparin ; and
4) combination streptokinase, rl-PA and intravenous heparin . The
planned recruitment of 41,600 patients in 1 .500 sites from 15
countries is expected to be completed by December 1992 and will
enable detection of a 15% reduction or 1 % absolute difference in
mortality compared with that associated with standard therapy
(streptokinase and subcutaneous heparin) .
In designing the trial, two important issues were directly
Few areas in medicine have witnessed as radical a change in
the past decade as that of the management of acute myocar-
dial infarction, in which thrombolytic therapy has emerged
as a central focus of cardiovascular therapeutics. Although
intravenous thrombolytic therapy was rarely used until the
mid-1960s, it has become the standard of care for appropri-
ately eligible patients in the past 3 years (1). In concert with
an acceptance c` this more aggressive therapeutic interven-
tion was the willingness of clinicians to exchange an inci-
dence of intracerebral hemorrhage of approximately 0 .5%
for a 30% relati•- e reduction in mortality (2) . Despite this
major advance, recent large trials of thrombolytic therapy
point to a persistently high 30-day mortality rate of 10%
irrespective of which thrombolytic agent is administered
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addressed
. First, a strategy was developed to provide assurance of
patient safety during large scale invest'iggational use of an aggres-
.,ive thrombolytic regimen
. This includes fascimile transmission of
a one-page safety summary form to the Data Coordinating Center
within 24 h of death or discharge, acceptance of the concept of
"net clinical benefit" and close surveillance of the trial's progress
by the independent Data and Safety Monitoring Committee.
Second, to avoid potential conflict of interest beyond elimination
of any position of financial equity, the Steering Committee unan-
imousty voted to prohibit any honoraria for speaking engage-
ments
. payment for consultarry or travel or reimbursement of
any kind from any of the five corporate sponsors until t year after
publication of the results . Incorporation of these approaches may
facilitate the design of future largo scale randomized trials in
cardiovascular medicine .
(J Am Coll Cardiol 1992:19:1123-8)
(3
.4).
Moreover, significant residual left ventricular dysfunc-
tion despite thrombolytic therapy suggests that additional
therapeutic strategies are needed .
However, as the opportunity for further major reduction
in mortality becomes attenuated, it behooves investigators
to pay particular attention to any incremental risk associated
with new therapy. In the course of designing a large scale
clinical trial of different thrombolytic regimens, we . the
Steering Committee, became acutely aware of the need to
ensure patient safety if more aggressive pharmacologic reg-
imens
. which pose a potentially higher risk for serious
bleeding complications (5-8), were contemplated .
The second major issue that the committee faced was the
need for industrial sponsorship in the design, execution,
publication and presentation of the study's results (9-I1). It
is the purpose of this report to communicate the guidelines
and safeguards that address the important issues of patient
safety and investigator conflict of iuierest in a large scale
international clinical trial of myocardial reperfusion .
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Protocol Design
The primary objective of the Global Utilization of Strep-
tokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO) trial is to establish whether
rapid restoration of infarct vessel patency and sustained
reperfusion favorably affect survival outcome . Initially,
three intravenous thrombolytic strategies were selected for
comparison
: 1) accelerated dosing of recombinant tissue-
type plasminogen activator (rt-PA), which is associated with
75% potency of the infarct-related vessel at 60 min and 85%
patency of this artery at 90 min (7,12,13); 2) combination
rt-PA and streptokinase therapy, which has been demon-
strated to avoid reocclusion in 95% of patients who have
successful reperfusion (14-16)
; and 3) streptokinase therapy,
which is the confirmed reference therapy from previous large
scale trials (4,17,18)
. All three thrombolytic regimens in-
clude oral aspirin and intravenous heparin, the latter ad-
justed to maintain a 2- to 2.5-fold elevation of the activated
partial thromboplastin time for at least 48 h .
Impact of ISIS-3. At the American College of Cardiology
meetings in March 1991, preliminary results from the largest
myocardial reperfusion trial performed to date, the Third
International Study of Infarct Survival (ISIS-3), were re-
ported (4) . In this trial of 46,115 patients who were randomly
assigned to receive one of three alternative thrombolytic
drugs (streptokinase, duteplase or anistreplase), a secondary
randomization was used to allocate patients to receive either
subcutaneous or no heparin
. There was no significant differ-
ence in 35-day mortality among the thrombolytic agents or
with the use of subcutaneous heparin . However, when the
preliminary data from ISIS-3 were combined with data from
the Gruppo Italiano per In Studio Della Sopravivenza
nell'Infarto Miocardico (GISSI-2) (17) and the International
Study Group
(18), there was a reduction in mortality from
10% for no heparin (32,573 patients) to 9 .5% for subcutane-
ous heparin (32,544 patients) (p < 0 .05) (4) . Although a
higher rate of probable intracerebral hemorrhage and trans-
fusion was noted in patients receiving subcutaneous heparin
than in control patients in both trials, the overall outcomes
favored the use of subcutaneous heparin . To date there have
been no large scale, controlled, mortality reduction trials of
intravenous heparin coupled with thrombolytic therapy .
As a result of these findings, we modified the GUSTO
trial to incorporate a fourth arm of intravenous streptokinase
with subcutaneous heparin. This regimen was perceived to
be the best reference standard because it had been evaluated
in >20,000 patients (3,4,18) . Thus, this fourth arm is in-
tended to provide an authentic and contemporary reference
with which the other three experimental arms can be com-
pared in order to appropriately test the probability of lower
mortality without an undue increase in the risk of intraccre-
bral hemorrhage .
Entry criteria and sample size . In GUSTO, as in the other
large scale trials, the patient entry criteria are broad in
scope, with no upper age or blood pressure limit or exclusion
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for many of the reasons patients are often deemed ineligible
for thrombolytic therapy (1) . Only active bleeding, history of
stroke or central nervous system disease, noncompressible
punctures, recent trauma or surgical treatment and previous
streptokinase or anistrcplase therapy represent absolute
contraindications for enrollment
. Patients with other relative
contraindications to thrombolytic therapy can be entered or
withheld at the discretion of the investigators . The primary
end point is 30-day mortality and the sample size of 41,600
patients is adequate to detect a 15% reduction or I".b
absolute difference in mortality, whichever is smaller, for
any of the experimental therapies (alpha 0.05, beta 0.20,
two-tailed)
. The trial is being conducted in 14 countries in
four continents (see Appendix) with the randomization cen-
ter and data coordination at Duke University and interme-
diate coordinating center in Leuven, Belgium
. Although the
trial design had input from the sponsor in the planning phase,
the protocol was approved by the Steering Committee inde-
pendently of the sponsor, and the fourth arm was conceived
and ratified by vote of the Steering Committee .
Investigator-Patient Relations
With the intravenous thrombolytic regimens that are
being assessed, it is clear that the potential for serious
bleeding complications is increased compared with that of
standard therapy
. Although the use of combination or accel-
erated ft-PA therapy has not been associated with an appar-
ent increase in intracerebral hemorrhage, the most dreaded
untoward consequence of such therapy, only 500 and 1,000
patients, respectively, have been studied with each regimen
.
This is far short of the number of patients needed to reliably
exclude a modest increase in bleeding risk . In GUSTO, the
large number of patients (anticipated up to 100) who may be
treated on any particular day mandates very close and
contemporary surveillance of safety data and advance spec-
ification of boundaries or guidelines for stopping an arm of
the trial (19) .
Currently, thrombolytic therapy for acute myocardial
infarction results in an approximate I in 200 (0 .5%) event
rate of intracerebral hemorrhage . In Table I, using this rate
as a standard of reference for 1,000 patients receiving a
thrombolytic regimen, the 95% confidence interval data are
presented for expected versus observed stroke rates . If the
observed rate of hemorrhagic stroke significantly exceeds
the accepted standard (eg, five hemorrhagic strokes among
1 .000 patients) . the Data and Safety Monitoring Committee
will be responsible for adjudicating the data and making a
recommendation to the Steering Committee . If a safety
problem is evident, possible recommendations would in-
clude either changing the treatment regimen or discontinuing
one arm of the trial
. Ultimately, the Steering Committee will
decide to accept or modify such a recommendation.
Most important in this process is the rapid and efficient
on-site acquisition of data concerning any untoward clinical
events . Within 24 h of death or discharge, a one-page safety
IACC Vol. 1 7 . No. 6
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Table I. Probabilities and Confidence Intervals for the Incidence of Stroke Based on an Expected
Hemorrhagic Stroke Rate of
0 .51/,
in 1 .1)00 Patients Receiving
"I hrombotytic Therapy
No . of Strokes
	
95, Confidence
Observed Intervals
110.1101 0-0.29
510.5901 0.06-0.94
1011.0% 0.38-1,62
IS 11 .5%) 0
.7-2.3
summary form is transmitted by facsimile to the Data
Coordinating Center detailing whether the patient had a
stroke or a life-threatening bleeding event . The hemorrhagic
stroke rate will be ascertained on a biweekly basis and if
clear-cut trends emerge in comparing observed rates with
representative data from Table 1, discussion with the Data
and Safety Monitoring Committee may become necessary .
Tmo key issues mill require judgment on the part f the
Data and Safety Monitoring Committee . First. the concept
of "net clinical benefit" will be considered . If the observed
rate of intracranial bleeding complications is higher than the
expected rate, it must be interpreted in the context of the
overall effect of treatment on mortality . Because >50% of
patients who experience intracranial hemorrhage ultimately
die, these patients are assigned to the mortality rather than
to the morbidity category . Hence, a therapy that simulta-
neously increased intracranial hemorrhage but decreased
total mortality might on balance be considered beneficial .
Second, the extensive quality assurance methods and the
inclusion of mandatory efforts for computer Iconographic or
nuclear magnetic resonance imaging should a neurologic
event occur in GUSTO could lead to greater reporting of
strokes than in previous megatrials. The reference streptoki-
nase plus subcutaneous heparin arm should provide impor-
tant perspective on this issue .
Investigator-Industry Relations
The sheer size of this trial, involving more than 1 .500
hospitals and several thousand investigators, reduces the
potential impact of biases attt ibuted to a single investigator
;
however, important potential conflicts of interest still exist
.
In Websteis Third New International Dirt beam,, a conflict
of interest is defined as a "conflict cetween the private
interests and official responsibilities of a person in a position
of trust." Although it usually implies the potential for direct
financial gain, such a conflict might subtly or even subcon-
sciously affect an investigator's objectivity
. Careful review
of the guidelines adopted by three large, multicenter. ran-
domized trials in cardiovascular medicine reveals some
potential gaps in procedures for avoiding unnecessary finan-
cial ties between clinical investigators and industry sponsors
(11,20) (Table 2). To avoid any financial linkage, it is clearly
desirable that the investigator have no equity interest such as
stock or stock options in a company sponsor and that there
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Pmbab :lhy of Having Robability of Having
--IArne
U
lfTv <IStake IfTue
Rae Is S Rate Is 0.5%
0.96 0 .04
11.78 0.62
0 .014 0.97
7005)
0.99
be no remuneration for a consultancy arrangement, exper-
tise or service during the course of the trial. Such guidelines
apply not only to the investigator but to his or her spouse,
dependents and family . This "freedom from equity or em-
ployment" rule, adopted by several designers of clinical
trials and organizations suet, as the American Medical As-
sociation (10) and the American Federation for Clinical
Research and institutions such as Harvard Medical School
(9). appears to represent an emerging consensus . There is
continued debate, however, exemplified by the subsequent
rejection as draconian of the draft guidelines from Septem-
ber 1989 of the National Institutes of Health and the Alcohol .
Drug Abuse and Mental Health Administration (21-25) . On
the other hand, the limitations of simple disclosure are well
recognized (26) .
The GUSTO Steering Committee decided to significantly
extend the standard criteria. By unanimous vote, it banned
honoraria paid by the trial sponsors for educational activities
or lectures and reimbursement for travel expenses. Investi-
gator travel related to the research project is being reim-
bursed from the study's budget . In recognition of the critical
time period after completion of the trial and dissemination of
the data . along with the possibility that any financial ties
during the phase of presentation of data might delicately
affect the tone or interpretation of a lecture, the Steering
Committee also extended the period for avoidance of any
financial ties to I year after formal publication of the trial's
primary results . In contrast, many other trials either have
not specified the duration of potential conflict of interest or
have ceased applying guidelines as soon as the data have
been publicized (Table 2).
The guidelines are applicable to all of the sponso s, which
in this trial include Bayer (New York, New York) ; CIBA-
Corning Diagnostics (Medfield, Massachusetts) ; Genentech
(South San Francisco. California); ICI Pharmaceuticals
(Wilmington, Delaware) and Sonofi Pharmaceuticals (Paris,
France) . In addition, these safeguards were adopted by the
Steering Committee and the Data Safety and Monitoring
Committee and all members of the Data Coordinating Cen-
ter
. At the level of participating site principal investigators,
written documentation is required that acknowledges the
lack of any equity interest in the sponsors . We believe that
such stringent guidelines, albeit not absolutely necessary,
are important to ensure the highest level of integrity for the
project throughout its execution and dissemination phases.
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Table 2 . Conflict of Interest Guidelines in Cardiovascular Clinical Trials and Medical Organizations
Source Stock . Equity.
Honoraria. Educational Travel Financial ''Time
ref. and Interest Consullancy Program Payments Expenses Window"
Investigation-Industry Relation
The freedom of c:.sigrl of the GUSTO protocol was the
first step of many to secure autonomy during the execution
of the trial . The processes for data collection, quality assur-
ance, management, access and analysis were all considered
in depth . The data are collected by study nurses at each of
the participating sites and quality assurance of these data is
achieved by source medical record documentation in a
randomly determined 10% of patients, as well as in all
patients with a major untoward event, such as intracerebral
hemorrhage or stroke . The monitoring is performed by an
independently contracted research organization (Clinical Re-
search International)
. After verification locally, all of the
data are forwarded to the Data Coordinating Center .
Throughout the trial, none of the sponsors or Steering
Committee members will have accss to the data unless a
change in trial design is required . The Data and Safety
Monitoring Committee, comprising five cardiologists, two
biostatisticians and one ethicist, will periodically review the
data at recruitment milestones of 3,000, 12,1)00 and 24,000
patients and of approximately 41,600 patients at the trial's
completion . However, even this independent committee will
interpret the safety and mortality data in a blinded fashion
.
For example, data will be labeled as treatment A, B, C or D
at one meeting and treatment W, X, Y or Z at another . A
similar set of guidelines is in place for the Food and Drug
Administration, which will receive regular reports of the
JACC (al. 19.
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trial's progress. The only exceptions to blinding of data will
be that two biostatisticians at the Data Coordinating Center
will know the code, and, for example, if there is an apparent
excess of intracerebral hemorrhage in one treatment arm,
then decoding the regimen may become necessary . The
sponsors will not have any knowledge of data unless there
has been a clear-cut safety problem that involves a possible
change in protocol, as described earlier . At the time of the
trial's completion, the primary data will be analyzed by the
Steering Committee and fully interpreted and discussed as a
group before any scientific or public presentation .
Conclusions
GUSTO represents the first United States-based large
scale myocardial reperfusion trial . Although such population
studies of tens of thousands of patients are considered
simple owing to the design and lack of comprehensive data
collection (the case report form is only three pages), the
process of reaching consensus about conflict of interest
policy and patient safety standards is complex . We clearly
recognize the pivotal need for dialogue and interaction
between industry and clinical investigators (20,27,28), Such
relations are essential for scientific and clinical development
as well as medical education . Extra care has been exercised
to maintain an arm's length relation between the industrial
Multicenter cardiovascular trials
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sponsors and the trialists of GUSTO during the project's
execution and dissemination phases . This will enhance un-
biased data acquisition and interpretation (29) . Furthermore .
this large scale effort is quite unique from the standpoint of
the Food and Drug Administration, which conventionally
requires complete medical research source documentation .
stringent participating site documentation and full character-
szaliua of ovary adverse A!,hocgh a,.r first p.^,_
assuring patient safety (30 .31) we have established some
special allowances with random auditing and rapid commu-
nication mechan ;e_ms that enable us to proceed with confi-
dence to test aggressive thromboijtic regimens . Incorpora-
tion of some
of the novel
..pprva,%cs adopted in the GUSTO
trial may facilitate the planning of other large scale random-
ized clinical trials in the future .
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